Sirolimus (rapamycin), everolimus, and temsirolimus have been approved by the FDA for the treatment of HER2-negative breast cancer, pancreatic neuroendocrine tumors, renal cell carcinomas, or angiomyolipomas. This evidence concerns the gene ERBB2 and pancreatic neuroendocrine tumor.